ALLMedicine™ Hodgkin Lymphoma Center
Research & Reviews 15,335 results
https://doi.org/10.1186/s13075-021-02460-8 10.1007/s12016-010-8198-y 10.1007/s12016-009-8194-2 10.1136/ard.2006.066068 10.1186/s13075-019-1867-1 10.1164/rccm.2106012 10.1002/art.39166 10.1093/rheumatology/kev016 10.2147/OARRR.S226695 10.1002/art.22204 10.1056/NEJMoa055120 10.1002/art.40114 10.1136/annrheumdis-2016-209909 10.5301/jsrd.5000205 10.1186/s13075-015-0872-2 10.1378/chest.13-2626 10.1371/journal.pone.0181692 10.1097/BOR.0000000000000656 10.1136/thoraxjnl-2018-211779 10.1056/NEJMoa1903076 10.2967/jnumed.116.174946 10.1016/j.ejrad.2016.10.001 10.1007/s00259-013-2514-8 10.1007/s12350-016-0649-2 10.4103/0972-3919.178335 10.4103/0972-3919.164018 10.1164/rccm.201308-1483ST 10.1088/0031-9155/60/18/7387 10.2967/jnumed.116.184796 10.4329/wjr.v6.i10.779 10.1002/art.38098 10.1164/rccm.200706-877OC 10.1093/rheumatology/ken271 10.2967/jnumed.114.147421 10.1164/rccm.201504-0780OC 10.1164/rccm.201508-1699ED 10.1016/j.ejrad.2016.09.014 10.1186/s12931-017-0556-3 10.2967/jnumed.115.163360 10.1097/MNM.0000000000000083 10.1007/s00259-011-1986-7 10.1007/s00259-009-1069-1 10.1136/annrheumdis-2018-21337652 10.1016/S1095-0397(99)00016-3
Arthritis Research & Therapy; Ledoult E, Morelle M et. al.
Mar 6th, 2021 - Interstitial lung disease is a common complication of systemic sclerosis (SSc-ILD), and it remains difficult to accurately predict its course. Progressing ILD could be more metabolically active, suggesting that the 18F-FDG tracer could be a tool i...
https://doi.org/10.1158/1078-0432.CCR-21-0133
Clinical Cancer Research : an Official Journal of the Ame... Wang C, Liu Y et. al.
Mar 6th, 2021 - Programmed death-1 (PD-1) blockade monotherapy is effective in relapsed/refractory classical Hodgkin lymphoma (cHL), but a subset of patients is recalcitrant to PD-1 inhibitors and only a minority of patients achieves durable remission. Effective ...
https://doi.org/10.1016/S2352-3026(21)00058-2
The Lancet. Haematology; Thanarajasingam G, Smedby KE et. al.
Mar 5th, 2021 - Late toxicities in non-Hodgkin lymphoma: extended follow-up matters.|2021|Thanarajasingam G,Smedby KE,LaCasce A,|
https://doi.org/10.1038/s41375-021-01193-6 10.1182/blood.2019000324 10.1200/JCO.2017.76.0793 10.1038/bmt.2015.332 10.1182/blood-2016-09-738385 10.1634/theoncologist.2017-0004 10.1016/j.bbmt.2018.08.028 10.1182/bloodadvances.2018019208 10.3324/haematol.2019.215962 10.1182/bloodadvances.2019001336 10.1182/blood-2018-02-811174 10.1200/JCO.2013.54.8800 10.1016/j.bbmt.2014.12.001 10.1016/j.bbmt.2018.12.758 10.1080/01621459.1999.10474144 10.1016/j.bbmt.2019.05.025 10.1200/JCO.2017.72.6869 10.1182/blood-2013-05-500801 10.4049/jimmunol.171.3.1272 10.1182/bloodadvances.2019000134 10.1016/j.bbmt.2016.06.010 10.1172/JCI124218 10.1002/cncr.32796 10.1007/s00277-020-04033-2 10.1016/j.clml.2020.04.003 10.1016/j.bbmt.2017.11.030
Leukemia Merryman RW, Castagna L et. al.
Mar 4th, 2021 - Anti-PD-1 monoclonal antibodies yield high response rates in patients with relapsed/refractory classic Hodgkin lymphoma (cHL), but most patients will eventually progress. Allogeneic hematopoietic cell transplantation (alloHCT) after PD-1 blockade ...
https://doi.org/10.1097/RLU.0000000000003634
Clinical Nuclear Medicine; Doss M, Nakhoda SK et. al.
Mar 4th, 2021 - We present a case of increased FDG uptake in the lymph nodes after COVID-19 vaccine administration. Restaging PET/CT scan of a 70-year-old woman with a history of multiple relapsed Hodgkin lymphoma showed muscle activity in the left upper arm late...
Guidelines 111 results
https://www.cancer.gov/types/lymphoma/hp/adult-hodgkin-treatment-pdq?cid=eb_govdel
National Cancer Institute
Jan 14th, 2021 - More than 75% of all newly diagnosed patients with adult HL can be cured with combination chemotherapy and/or radiation therapy.[2] Over the last five decades, U.S. national mortality has fallen more rapidly for adult HL than for any other maligna...
https://www.healio.com/news/hematology-oncology/20200709/lisocabtagene-maraleucel-car-t-shows-durable-response-in-large-bcell-nhl
Jul 8th, 2020 - In updated results of the pilot study, presented during the ASCO2020 Virtual Scientific Program, researchers showed that lisocabtagene maraleucel induced durable response as a second-line treatment in large B-cell non-Hodgkin lymphoma.
https://www.mdedge.com/hematology-oncology/article/223065/hodgkin-lymphoma/pembrolizumab-prolonged-pfs-vs-brentuximab
May 31st, 2020 - Pembrolizumab treatment significantly improved progression-free survival versus brentuximab vedotin in a recent randomized, phase 3 trial including patients with relapsed or refractory classical Hodgkin lymphoma, an investigator has reported.
https://www.healio.com/hematology-oncology/lymphoma/news/online/{b5b2d115-7000-4df9-8743-26711c3bbde1}/car-t-continues-to-show-durable-responses-in-indolent-non-hodgkin-lymphoma
May 30th, 2020 - Axicabtagene ciloleucel induced a 93% response rate among patients with relapsed or refractory indolent non-Hodgkin lymphoma, according to interim results of the phase 2 ZUMA-5 trial presented during the ASCO20 Virtual Scientific Program.
https://www.medpagetoday.com/meetingcoverage/asco/86783
May 30th, 2020 - Almost 100% of patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) responded to treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel, Yescarta), data from an ongoing study showed.
Drugs 81 results see all →
Clinicaltrials.gov 16,537 results
https://doi.org/10.1186/s13075-021-02460-8 10.1007/s12016-010-8198-y 10.1007/s12016-009-8194-2 10.1136/ard.2006.066068 10.1186/s13075-019-1867-1 10.1164/rccm.2106012 10.1002/art.39166 10.1093/rheumatology/kev016 10.2147/OARRR.S226695 10.1002/art.22204 10.1056/NEJMoa055120 10.1002/art.40114 10.1136/annrheumdis-2016-209909 10.5301/jsrd.5000205 10.1186/s13075-015-0872-2 10.1378/chest.13-2626 10.1371/journal.pone.0181692 10.1097/BOR.0000000000000656 10.1136/thoraxjnl-2018-211779 10.1056/NEJMoa1903076 10.2967/jnumed.116.174946 10.1016/j.ejrad.2016.10.001 10.1007/s00259-013-2514-8 10.1007/s12350-016-0649-2 10.4103/0972-3919.178335 10.4103/0972-3919.164018 10.1164/rccm.201308-1483ST 10.1088/0031-9155/60/18/7387 10.2967/jnumed.116.184796 10.4329/wjr.v6.i10.779 10.1002/art.38098 10.1164/rccm.200706-877OC 10.1093/rheumatology/ken271 10.2967/jnumed.114.147421 10.1164/rccm.201504-0780OC 10.1164/rccm.201508-1699ED 10.1016/j.ejrad.2016.09.014 10.1186/s12931-017-0556-3 10.2967/jnumed.115.163360 10.1097/MNM.0000000000000083 10.1007/s00259-011-1986-7 10.1007/s00259-009-1069-1 10.1136/annrheumdis-2018-21337652 10.1016/S1095-0397(99)00016-3
Arthritis Research & Therapy; Ledoult E, Morelle M et. al.
Mar 6th, 2021 - Interstitial lung disease is a common complication of systemic sclerosis (SSc-ILD), and it remains difficult to accurately predict its course. Progressing ILD could be more metabolically active, suggesting that the 18F-FDG tracer could be a tool i...
https://doi.org/10.1158/1078-0432.CCR-21-0133
Clinical Cancer Research : an Official Journal of the Ame... Wang C, Liu Y et. al.
Mar 6th, 2021 - Programmed death-1 (PD-1) blockade monotherapy is effective in relapsed/refractory classical Hodgkin lymphoma (cHL), but a subset of patients is recalcitrant to PD-1 inhibitors and only a minority of patients achieves durable remission. Effective ...
https://doi.org/10.1016/S2352-3026(21)00058-2
The Lancet. Haematology; Thanarajasingam G, Smedby KE et. al.
Mar 5th, 2021 - Late toxicities in non-Hodgkin lymphoma: extended follow-up matters.|2021|Thanarajasingam G,Smedby KE,LaCasce A,|
https://doi.org/10.1038/s41375-021-01193-6 10.1182/blood.2019000324 10.1200/JCO.2017.76.0793 10.1038/bmt.2015.332 10.1182/blood-2016-09-738385 10.1634/theoncologist.2017-0004 10.1016/j.bbmt.2018.08.028 10.1182/bloodadvances.2018019208 10.3324/haematol.2019.215962 10.1182/bloodadvances.2019001336 10.1182/blood-2018-02-811174 10.1200/JCO.2013.54.8800 10.1016/j.bbmt.2014.12.001 10.1016/j.bbmt.2018.12.758 10.1080/01621459.1999.10474144 10.1016/j.bbmt.2019.05.025 10.1200/JCO.2017.72.6869 10.1182/blood-2013-05-500801 10.4049/jimmunol.171.3.1272 10.1182/bloodadvances.2019000134 10.1016/j.bbmt.2016.06.010 10.1172/JCI124218 10.1002/cncr.32796 10.1007/s00277-020-04033-2 10.1016/j.clml.2020.04.003 10.1016/j.bbmt.2017.11.030
Leukemia Merryman RW, Castagna L et. al.
Mar 4th, 2021 - Anti-PD-1 monoclonal antibodies yield high response rates in patients with relapsed/refractory classic Hodgkin lymphoma (cHL), but most patients will eventually progress. Allogeneic hematopoietic cell transplantation (alloHCT) after PD-1 blockade ...
https://doi.org/10.1097/RLU.0000000000003634
Clinical Nuclear Medicine; Doss M, Nakhoda SK et. al.
Mar 4th, 2021 - We present a case of increased FDG uptake in the lymph nodes after COVID-19 vaccine administration. Restaging PET/CT scan of a 70-year-old woman with a history of multiple relapsed Hodgkin lymphoma showed muscle activity in the left upper arm late...
News 1,093 results
https://www.medscape.com/viewarticle/945856
Feb 15th, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Patients with cancer are considered at risk for COVID-19, but in some cases, could the infection be a good thing? A case report of a patient with ...
https://www.medscape.com/viewarticle/945496
Feb 8th, 2021 - NEW YORK (Reuters Health) - Lymphoma patients treated with B-cell-depleting anti-CD20 monoclonal antibodies, such as rituximab or obinutuzumab, may have worse outcomes from COVID-19 infection, according to a study from France. "More than 20 years ...
https://reference.medscape.com/viewarticle/944100
Jan 31st, 2021 - Waldenström macroglobulinemia (WM) is an indolent subtype of non-Hodgkin lymphoma (NHL) that affects small lymphocytes. WM is rare, accounting for approximately 2% of hematologic malignancies with 1500 cases diagnosed per year in the United States...
https://www.cancer.gov/types/lymphoma/hp/adult-hodgkin-treatment-pdq?cid=eb_govdel
National Cancer Institute
Jan 14th, 2021 - More than 75% of all newly diagnosed patients with adult HL can be cured with combination chemotherapy and/or radiation therapy.[2] Over the last five decades, U.S. national mortality has fallen more rapidly for adult HL than for any other maligna...
https://www.medscape.com/viewarticle/942494
Dec 10th, 2020 - For the first time, a chimeric antigen receptor (CAR) therapy has yielded a high response rate among patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL), including patients with follicular lymphoma (FL) and marginal zone lymphom...